Synergistic contributions of the functional groups of epinephrine to its affinity and efficacy at the β2 adrenergic receptor

Molecular Pharmacology

Volumn 65, Issue 5, 2004, Pages 1181-1190

  Liapakis, George ^a   Chan, Wai Chi ^b   Papadokostaki, Maria ^a   Javitch, Jonathan A ^b,c,d  

^a UNIVERSITY OF CRETE   (Greece)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c New York State Psychiatric Institute ^*  (United States)

^d NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ALPHA METHYLDOPAMINE; BETA 2 ADRENERGIC RECEPTOR; DOPAMINE; FUNCTIONAL GROUP; HALOSTACHINE; HYDROXYPHENETHYLAMINE; LIGAND; METHYLPHENETHYLAMINE; NORADRENALIN; NORFENEFRINE; OCTOPAMINE; OXEDRINE; PHENETHYLAMINE; PHENYLEPHRINE; UNCLASSIFIED DRUG;

ADDITION REACTION; ARTICLE; BINDING AFFINITY; BINDING SITE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BINDING; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; GENE MUTATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; REACTION OPTIMIZATION; SIGNAL TRANSDUCTION; WILD TYPE;

ADENYLATE CYCLASE; ADRENERGIC AGONISTS; ASPARAGINE; ASPARTIC ACID; BINDING SITES; CELLS, CULTURED; CYCLIC AMP; ENZYME ACTIVATION; EPINEPHRINE; HUMANS; MUTAGENESIS, SITE-DIRECTED; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, ADRENERGIC, BETA-2;

EID: 2142703828     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.65.5.1181     Document Type: Article

References (40)

1. Ballesteros JA, Jensen AD, Liapakis G, Rasmussen SG, Shi L, Gether U, and Javitch JA (2001) Activation of the beta 2-adrenergic receptor involves disruption of an ionic lock between the cytoplasmic ends of transmembrane segments 3 and 6. J Biol Chem 276:29171-29177.
2. Ballesteros J and Weinstein H (1995) Integrated methods for the construction of three-dimensional models of structure-function relations in G protein-coupled receptors. Methods Neurosci 25:366-428.
3. Belleau B, DiTullio V, and Godin D (1969) The mechanism of irreversible adrenergic blockade by N-carbethoxydihydroquinolines-model studies with typical serine hydrolases. Biochem Pharmacol 18:1039-1044.
4. 50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
5. Cho W, Taylor LP, Mansour A, and Akil H (1995) Hydrophobic residues of the D2 dopamine receptor are important for binding and signal transduction. J Neurochem 65:2105-2115.
6. Chung FZ, Wang CD, Potter PC, Venter JC, and Fraser CM (1988) Site-directed mutagenesis and continuous expression of human beta-adrenergic receptors. Identification of a conserved aspartate residue involved in agonist binding and receptor activation. J Biol Chem 263:4052-4055.
7. Del Carmine R, Ambrosio C, Sbraccia M, Cotecchia S, Ijzerman AP, and Costa T (2002) Mutations inducing divergent shifts of constitutive activity reveal different modes of binding among catecholamine analogues to the beta(2)-adrenergic receptor. Br J Pharmacol 135:1715-1722.
8. Farahbakhsh ZT, Hideg K, and Hubbell WL (1993) Photoactivated conformational changes in rhodopsin: a time-resolved spin label study. Science (Wash DC) 262: 1416-1419.
9. Farrens DL, Altenbach C, Yang K, Hubbell WL, and Khorana HG (1996) Requirement of rigid-body motion of transmembrane helices for light activation of rhodopsin. Science (Wash DC) 274:768-770.
10. Gether U, Lin S, Ghanouni P, Ballesteros JA, Weinstein H, and Kobilka BK (1997) Agonists induce conformational changes in transmembrane domains III and VI of the beta2 adrenoceptor. EMBO (Eur Mol Biol Organ) J 16:6737-6747.
11. Ghanouni P, Gryczynski Z, Steenhuis JJ, Lee TW, Farrens DL, Lakowicz JR, and Kobilka BK (2001) Functionally different agonists induce distinct conformations in the G protein coupling domain of the beta 2 adrenergic receptor. J Biol Chem 276:24433-24436.
12. Gouldson PR, Snell CR, and Reynolds CA (1997) A new approach to docking in the beta 2-adrenergic receptor that exploits the domain structure of G-protein-coupled receptors. J Med Chem 40:3871-3886.
13. Javitch JA, Ballesteros JA, Weinstein H, and Chen J (1998) A cluster of aromatic residues in the sixth membrane-spanning segment of the dopamine D2 receptor is accessible in the binding-site crevice. Biochemistry 37:998-1006.
14. Javitch JA, Fu D, Liapakis G, and Chen J (1997) Constitutive activation of the beta2 adrenergic receptor alters the orientation of its sixth membrane-spanning segment. J Biol Chem 272:18546-18549.
15. Kearn CS, Greenberg MJ, DiCamelli R, Kurzawa K, and Hillard CJ (1999) Relationships between ligand affinities for the cerebellar cannabinoid receptor CB1 and the induction of GDP/GTP exchange. J Neurochem 72:2379-2387.
16. Kobilka BK (1995) Amino and carboxyl terminal modifications to facilitate the production and purification of a G protein-coupled receptor. Anal Biochem 231: 269-271.
17. Leff P (1995) The two-state model of receptor activation. Trends Pharmacol Sci 16:89-97.
18. Liapakis G, Ballesteros JA, Papachristou S, Chan WC, Chen X, and Javitch JA (2000) The forgotten serine. A critical role for Ser-2035.42 in ligans binding to and activation of the beta 2-adrenergic receptor. J Biol Chem 275:37779-37788.
19. Luo X, Zhang D, and Weinstein H (1994) Ligand-induced domain motion in the activation mechanism of a G-protein-coupled receptor. Protein Eng 7:1441-1448.
20. Marjamaki A, Frang H, Pihlavisto M, Hoffren AM, Salminen T, Johnson MS, Kallio J, Javitch JA, and Scheinin M (1999) Chloroethylclonidine and 2-aminoethyl methanethiosulfonate recognize two different conformations of the human alpha(2A)-adrenergic receptor. J Biol Chem 274:21867-21872.
21. Noda K, Feng YH, Liu XP, Saad Y, Husain A, and Karnik SS (1996) The active state of the ATI angiotensin receptor is generated by angiotensin II induction. Biochemistry 35:16435-16442.
22. Nordstedt C and Fredholm BB (1990) A modification of a protein-binding method for rapid quantification of cAMP in cell-culture supernatants and body fluid. Anal Biochem 189:231-234.
23. Perez DM, Hwa J, Gaivin R, Mathur M, Brown F, and Graham RM (1996) Constitutive activation of a single effector pathway: evidence for multiple activation states of a G protein-coupled receptor. Mol Pharmacol 49:112-122.
24. Rasmussen SG, Jensen AD, Liapakis G, Ghanouni P, Javitch JA, and Gether U (1999) Mutation of a highly conserved aspartic acid in the beta2 adrenergic receptor: constitutive activation, structural instability and conformational rearrangement of transmembrane segment 6. Mol Pharmacol 56:175-184.
25. Rees S, Coote J, Stables J, Goodson S, Harris S, and Lee MG (1996) Bicistronic vector for the creation of stable mammalian cell lines that predisposes all antibiotic-resistant cells to express recombinant protein. Biotechniques 20:102-104, 106, 108-110.
26. Resek JF, Farahbakhsh ZT, Hubbell WL, and Khorana HG (1993) Formation of the meta II photointermediate is accompanied by conformational changes in the cytoplasmic surface of rhodopsin. Biochemistry 32:12025-12032.
27. Samama P, Cotecchia S, Costa T, and Lefkowitz RJ (1993) A mutation-induced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model. J Biol Chem 268:4625-4636.
28. Seifert R, Gether U, Wenzel-Seifert K, and Kobilka BK (1999) Effects of guanine, inosine and xanthine nucleotides on beta(2)-adrenergic receptor/G(s) interactions: evidence for multiple receptor conformations. Mol Pharmacol 56:348-358.
29. Shi L and Javitch JA (2002) The binding site of aminergic G protein-coupled receptors: the transmembrane segments and second extracellular loop. Annu Rev Pharmacol Toxicol 42:437-467.
30. Shi L, Liapakis G, Xu R, Guarnieri F, Ballesteros JA, and Javitch JA (2002) Beta2 adrenergic receptor activation. Modulation of the proline kink in transmembrane 6 by a rotamer toggle switch. J Biol Chem 277:40989-40996.
31. Strader CD, Candelore MR, Hill WS, Sigal IS, and Dixon RA (1989) Identification of two serine residues involved in agonist activation of the beta-adrenergic receptor. J Biol Chem 264:13572-13578.
32. Strader CD, Fong TM, Tota MR, Underwood D, and Dixon RA (1994) Structure and function of G protein-coupled receptors. Annu Rev Biochem 63:101-132.
33. Strader CD, Sigal IS, Candelore MR, Rands E, Hill WS, and Dixon RA (1988) Conserved aspartic acid residues 79 and 113 of the beta-adrenergic receptor have different roles in receptor function. J Biol Chem 263:10267-10271.
34. Strange PG (1999) G-protein coupled receptors: conformations and states. Biochem Pharmacol 58:1081-1088.
35. Swaminath G, Xiang Y, Lee TW, Steenhuis J, Parnot C, and Kobilka BK (2003) Sequential binding of agonists to the beta 2 adrenoceptor: kinetic evidence for intermediate conformational states. J Biol Chem 279:686-691.
36. Tachibanaki S, Imai H, Mizukami T, Okada T, Imamoto Y, Matsuda T, Fukada Y, Terakita A, and Shichida Y (1997) Presence of two rhodopsin intermediates responsible for transducin activation. Biochemistry 36:14173-14180.
37. Ward SD, Curtis CA, and Hulme EC (1999) Alanine-scanning mutagenesis of transmembrane domain 6 of the M(1) muscarinic acetylcholine receptor suggests that Tyr381 plays key roles in receptor function. Mol Pharmacol 56:1031-1041.
38. Watts VJ, Wiens BL, Cumbay MG, Vu MN, Neve RL, and Neve KA (1998) Selective activation of Galphao by D2L dopamine receptors in NS20Y neuroblastoma cells. J Neurosci 18:8692-8699.
39. Weiss JM, Morgan PH, Lutz MW, and Kenakin TP (1996) The cubic ternary complex receptor-occupancy model II. Understanding apparent affinity. J Theor Biol 178: 169-182.
40. Wieland K, Zuurmond HM, Krasel C, Ijzerman AP, and Lohse MJ (1996) Involvement of Asn-293 in stereospecific agonist recognition and in activation of the beta 2-adrenergic receptor. Proc Natl Acad Sci USA 93:9276-9281.